July 21 (Reuters) - Helius Medical Technologies Inc HSDT.O:
HELIUS ANNOUNCES POSITIVE OUTCOME OF THE PORTABLE NEUROMODULATION STIMULATOR PONS® STROKE REGISTRATIONAL PROGRAM AND UPCOMING SUBMISSION TO FDA UNDER BREAKTHROUGH DESIGNATION
HELIUS MEDICAL TECHNOLOGIES INC - STUDIES CONFIRM MINIMAL ADVERSE EVENTS WITH PONS THERAPY
HELIUS MEDICAL TECHNOLOGIES: PLANNING TO FILE A SUBMISSION TO FDA FOR INDICATION IN STROKE DURING Q3 OF 2025
Source text: ID:nGNX4szG36
Further company coverage: HSDT.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.